Biotech inquiry
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Biotech inquiry
BRITISH BIOTECH is to face an inquiry by members of parliament on 8 July, a member of the House of Commons Science and Technology Select Committee said yesterday.
MP Ian Gibson said the committee had written to British Biotech's chief executive, Keith McCullagh, and sacked head of clinical trials, Andrew Millar, asking them to attend on that date. A follow-up hearing is likely to be held on 15 July.
Mr Gibson said the committee was particularly concerned over allegations that senior executives had sold shares just ahead of the abandonment of former lead cancer drug Batimastat.
It also wants to investigate allegations that British Biotech misled shareholders through over-optimistic statements on other drugs.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments